Literature DB >> 16258794

[Total risk for cardiovascular disease. At what point is medical prophylactic medication useful?].

H Gohlke1, C von Schacky.   

Abstract

Despite the epidemiological importance of coronary artery disease: cardiovascular events are rare from the individual viewpoint. There is considerable uncertainty when to start medical treatment. A given risk factor modification results in a relative risk reduction independent of the global risk. Therefore the global risk determines the absolute benefit of a preventive measure. The global risk can be estimated using different scoring systems. Using the global risk and the expected relative risk reduction, the number needed to treat (NNT) to avoid one event or cardiac death can be calculated. The NNT is a measure for the usefulness of a preventive intervention. A NNT of <200 appears acceptable for primary prevention. This can be achieved with pharmacological preventive strategies if the global risk of 10 years is > or =20%. As age is one of the most important risk predictors the need for treatment at comparable risk factor constellations is age dependent. Risk stratification with estimation of the NNT is therefore important for the decision to treat or not to treat.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16258794     DOI: 10.1007/s00392-005-1302-2

Source DB:  PubMed          Journal:  Z Kardiol        ISSN: 0300-5860


  16 in total

1.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

2.  Estimates of global and regional potential health gains from reducing multiple major risk factors.

Authors:  Majid Ezzati; Stephen Vander Hoorn; Anthony Rodgers; Alan D Lopez; Colin D Mathers; Christopher J L Murray
Journal:  Lancet       Date:  2003-07-26       Impact factor: 79.321

3.  Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy: findings for 5 large cohorts of young adult and middle-aged men and women.

Authors:  J Stamler; R Stamler; J D Neaton; D Wentworth; M L Daviglus; D Garside; A R Dyer; K Liu; P Greenland
Journal:  JAMA       Date:  1999-12-01       Impact factor: 56.272

4.  Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Münster (PROCAM) study.

Authors:  Gerd Assmann; Paul Cullen; Helmut Schulte
Journal:  Circulation       Date:  2002-01-22       Impact factor: 29.690

5.  Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme.

Authors: 
Journal:  Eur Heart J       Date:  2001-04       Impact factor: 29.983

6.  At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention?

Authors:  M Johannesson
Journal:  Eur Heart J       Date:  2001-06       Impact factor: 29.983

7.  Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project.

Authors:  R M Conroy; K Pyörälä; A P Fitzgerald; S Sans; A Menotti; G De Backer; D De Bacquer; P Ducimetière; P Jousilahti; U Keil; I Njølstad; R G Oganov; T Thomsen; H Tunstall-Pedoe; A Tverdal; H Wedel; P Whincup; L Wilhelmsen; I M Graham
Journal:  Eur Heart J       Date:  2003-06       Impact factor: 29.983

8.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

Authors:  J R Downs; M Clearfield; S Weis; E Whitney; D R Shapiro; P A Beere; A Langendorfer; E A Stein; W Kruyer; A M Gotto
Journal:  JAMA       Date:  1998-05-27       Impact factor: 56.272

9.  [Classical risk factors for myocardial infarction and total mortality in the community--13-year follow-up of the MONICA Augsburg cohort study].

Authors:  J Heidrich; J Wellmann; H-W Hense; E Siebert; A D Liese; H Löwel; U Keil
Journal:  Z Kardiol       Date:  2003-06

10.  A strategy to reduce cardiovascular disease by more than 80%.

Authors:  N J Wald; M R Law
Journal:  BMJ       Date:  2003-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.